MDM2 and chronic myelogenous leukemia, BCR-ABL1 positive: The down-regulation of MDM2 may indicate the therapeutic effect of nilotinib on CML cells, although MDM2 was still significantly overexpressed after 12 months of nilotinib treatment compared to CTRLs.